Quick Answer
IGC Pharma, Inc. reported Operating Income of -$7.45 million for fiscal year 2025.
IGC Pharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.45M | +24.0% |
| 2024 | -$9.80M | +15.3% |
| 2023 | -$11.57M | +25.0% |
| 2022 | -$15.43M | -76.8% |
| 2021 | -$8.72M | -27.1% |
| 2020 | -$6.86M | -47.8% |
| 2019 | -$4.64M | -159.5% |
| 2018 | -$1.79M | +12.9% |
| 2017 | -$2.05M | +29.3% |
| 2016 | -$2.91M | +33.1% |
| 2015 | -$4.34M | -71.8% |
| 2014 | -$2.53M | -1.8% |
| 2013 | -$2.48M | +66.9% |
| 2012 | -$7.51M | +52.7% |
| 2011 | -$15.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.90M | -64.7% | -52.2% |
| June 30, 2025 | -$1.91M | +20.5% | -1.4% |
| December 31, 2024 | -$1.88M | +37.4% | -6.7% |
| September 30, 2024 | -$1.76M | +29.3% | +26.5% |
| June 30, 2024 | -$2.40M | -12.0% | +20.1% |
| December 31, 2023 | -$3.00M | -31.6% | -20.4% |
| September 30, 2023 | -$2.49M | -0.1% | -16.5% |
| June 30, 2023 | -$2.14M | +23.7% | +6.1% |
- IGC Pharma, Inc. showed an increase of +24.0% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, IGC Pharma, Inc.’s operating income has grown by 53.1% (from -$15.89 million to -$7.45 million).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: